Lg-Octaplas (Human Plasma Protein)

Human plasma protein in Lg-Octaplas provides fibrinogen, prothrombin, and multiple clotting factors together with albumin and globulins. When administered intravenously, these proteins replenish deficient factors, enhance clot formation, and increase oncotic pressure, thereby helping to stop bleeding and restore intravascular volume.

The dose of Lg-Octaplas is individualized and determined by the prescribing clinician based on the patient’s specific coagulation deficit, body weight, severity of bleeding, and clinical setting. Dosing calculations are performed by the healthcare professional and are not standardized in public literature.

Safety data for Lg-Octaplas in pregnancy and lactation are limited; the product should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess each case carefully and follow local regulatory guidance.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lg-Octaplas. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lg-Octaplas is a lyophilized plasma protein fraction that offers a broad spectrum of clotting factors in a stable, reconstitutable form, whereas fresh frozen plasma provides whole plasma but requires cold storage and rapid use. Compared with specific factor concentrates, Lg-Octaplas delivers multiple factors simultaneously, which can be advantageous in complex coagulopathies or massive bleeding.

Lg-Octaplas should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The lyophilized powder remains stable until reconstitution; once reconstituted, it should be used promptly according to the product’s prescribing information and discarded if not used within the recommended time frame.

Lg-Octaplas is supplied as a lyophilized powder that must be reconstituted with the appropriate diluent under aseptic conditions. The resulting solution is administered by intravenous infusion, typically through a peripheral or central line, with infusion rates adjusted by the treating physician based on the patient’s clinical response and tolerance.

The most serious adverse events linked to Lg-Octaplas include severe allergic reactions such as anaphylaxis, transfusion‑related acute lung injury (TRALI), and rare transmission of infectious agents despite rigorous donor screening. Clinicians should monitor patients closely for signs of respiratory distress, hypotension, or unexpected bleeding during and after infusion.

Lg-Octaplas is contraindicated in individuals with known hypersensitivity to human plasma proteins or any of the product’s excipients. It should also be avoided in patients with a history of severe anaphylactic reactions to plasma‑derived therapies, and used with caution in those with uncontrolled volume overload, severe cardiac or renal failure, unless the clinical benefit justifies the risk.